Barbaryan Aram, Bailuc Stefania, Poddutoori Padma, Richardson Aida, Mirrakhimov Aibek E
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Department of Medicine, HSHS Saint Mary's Hospital, Decatur, IL, USA.
Case Rep Oncol Med. 2017;2017:4972017. doi: 10.1155/2017/4972017. Epub 2017 Apr 6.
Hypercalcemia in patients with cancer is a common laboratory finding affecting up to 44% of that patient population. 1,25-Dihydroxyvitamin D mediated hypercalcemia is one of the rare mechanisms of this endocrine emergency in cancer patients. It is even rarer for solid organ neoplasms to present with hypercalcemia mediated through the production of 1,25-dihydroxyvitamin D. We report a case of a 77-year-old female who presented to the hospital with hypercalcemia and later was found to have metastatic gastrointestinal stromal tumor. There have been only 5 cases of gastrointestinal stromal tumor described in literature resulting in hypercalcemia. In our case, the mechanism of hypercalcemia was thought to be related to overproduction of 1,25-dihydroxyvitamin by tumor cells. The patient had a favorable response to imatinib with normalization of serum calcium level. Unfortunately, she developed fluid retention due to imatinib which was discontinued resulting in relapse of hypercalcemia that was resistant to all other treatment options.
癌症患者的高钙血症是一种常见的实验室检查结果,影响多达44%的患者群体。1,25-二羟维生素D介导的高钙血症是癌症患者这种内分泌急症的罕见机制之一。实体器官肿瘤通过产生1,25-二羟维生素D导致高钙血症的情况更为罕见。我们报告一例77岁女性患者,因高钙血症入院,后来被发现患有转移性胃肠道间质瘤。文献中仅描述了5例胃肠道间质瘤导致高钙血症的病例。在我们的病例中,高钙血症的机制被认为与肿瘤细胞过度产生1,25-二羟维生素有关。患者对伊马替尼反应良好,血清钙水平恢复正常。不幸的是,她因伊马替尼出现液体潴留,停用伊马替尼后导致高钙血症复发,且对所有其他治疗方案均耐药。